1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

  • May 2019
  • 84 pages
  • ID: 5783495
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Summary
Parkinson’s disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages.Cognitive and behavioral complications of Parkinson’s disease (PD) are common.

In particular, PD-associated dementia and PD-associated psychosis are highly prevalent and associated with a large disease burden.

There is a pressing unmet need within Parkinson’s disease (PD), as well as PD-associated dementia and PD-associated psychosis, for more effective disease-modifying pharmacotherapies.Although current therapies can provide patients with symptomatic relief, there are no commercially available agents capable of preventing or slowing the course of Parkinson’s disease (PD) or its behavioral complications.

This reflects the complexity of these diseases and the incomplete understanding of disease pathogenesis.

There is considerable evidence that R&D within Parkinson’s disease (PD) is thriving, despite the high risk of failure associated with product development.The Parkinson’s disease (PD) pipeline is large and diverse, comprising 456 active products.

The pipeline is also highly innovative, as 51.1% of pipeline products with a disclosed molecular target are first-in-class. This is notably higher than the proportion across the industry as a whole, which is approximately 40%.

Analysis of the PD pipeline demonstrates a shift in focus from symptomatic alleviation to potential disease-modifying strategies. The pipeline comprises a range of novel mechanisms not observed in the market, including therapies that promote neurogenesis or immunomodulatory effects, and therapies that reduce neurotoxicity by preventing aggregation of misfolded proteins.

Far fewer products are in development for behavioral complications of PD.There are 16 products in development for PD-associated dementia, of which 12 have a disclosed molecular target.

However, encouragingly, the majority of these products-nine in total-are first-in-class.Only six pipeline products have been identified within the PD-associated psychosis pipeline, five of which have a disclosed molecular target.

However, none of these products are first-in-class.

Less than a third of products in active development for Parkinson’s disease (PD), PD-associated dementia, or PD-associated psychosis have prior involvement in licensing or co-development deals.Notably, products associated with the largest deal values are predominately first-in-class, a trend that is attributable to the stronger commercial potential of first-in-class products.

Additionally, some of the largest deal values relate to gene therapies, examples of which include VYAADC-01, ‘Gene Therapy to Inhibit SNCA for Neurology,’ AXO-Lenti-PD, and OXB-101. This provides further evidence that pharma companies are diversifying their approaches by investing more substantially in more innovative molecule types.

However, of the 467 products in active development within these indications, 326 (69.8%) have no prior involvement in licensing or co-development deals and therefore represent potential investment opportunities. This includes 96 first-in-class products that act on a diverse range of targets.

The report “Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects” focuses on Parkinson’s disease (PD), as well as PD-associated dementia and PD-associated psychosis, two behavioral complications of PD associated with large quality-of-life impairments and burden of care.

The catalysts and objectives for this report are to:

- Evaluate the pipeline for PD and its associated indications and identify all first-in-class programs.
- Integrate all first-in-class molecular targets identified in the pipeline into a proprietary matrix assessment, which assesses the rationale for therapeutic intervention based on a number of factors.
- Examine the preclinical and clinical evidence for the most promising first-in-class targets in the pipeline.
- Identify key players and deals within the landscape for PD and its behavioral complications.

Scope
- The PD pipeline is large, with 456 programs in active development. Far fewer products are in development for the behavioral complications of PD. There are 16 products in development for PD-associated dementia and six products in development for PD-associated psychosis. What proportion of these products across PD and PD behavioral complications are first in class? How does first-in-class innovation vary by development stage and molecular target class?
- Innovative molecular target groups identified in the pipeline include immunomodulators, neuroprotectants, and protein misfolding and aggregation. Which molecular target classes are prominently represented in the overall and first-in-class pipelines for PD and PD behavioral complications?
- There are 351 companies active across PD and PD behavioral complications. Which companies have the most first-in-class assets in development? Which companies are highly active in terms of licensing and co-development deals for first-in-class innovation?

Reasons to buy
-Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for PD. Overviews of PD-associated dementia and PD-associated psychosis are also provided.
- Analyze the pipelines for PD, PD-associated dementia, and PD-associated psychosis, and stratify them by stage of development, molecule type, and molecular target.
- Assess the therapeutic potential of first-in-class molecular targets. Using proprietary matrix assessments, first-in-class molecular targets for PD and PD-associated dementia have been assessed and ranked according to clinical potential. A matrix assessment is not provided for PD-associated psychosis due to a lack of first-in-class innovation. Promising first-in-class targets for PD and PD-associated dementia have been reviewed in greater detail.
- Analyze company strategies in prior deals through case studies of key deals for PD first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($6995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2019

Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2019

  • $ 3500
  • June 2019

Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2019SummaryMetabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 9 molecules. Out of which approximately ...

Dyskinesia Global Clinical Trials Review, H1, 2019

Dyskinesia Global Clinical Trials Review, H1, 2019

  • $ 2500
  • May 2019

Dyskinesia Global Clinical Trials Review, H1, 2019SummaryGlobalData’s clinical trial report, “Dyskinesia Global Clinical Trials Review, H1, 2019" provides an overview of Dyskinesia clinical trials ...

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019

  • $ 3500
  • May 2019

Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2019SummaryMetabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 23 molecules. Out of which approximately ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on